Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494.

Trial Profile

A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2019

At a glance

  • Drugs Upadacitinib (Primary) ; Tofacitinib
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 03 Apr 2019 Upadacitinib pharmacokinetic data from 12 studies spanning phase I , II and III clinical trials utilizing IR and ER formulations were combined and analyzed simultaneously using non-linear mixed-effects modeling; results published in the Clinical Pharmacokinetics
    • 26 Oct 2017 Results (n=573) assessing population pharmacokinetics of Upadacitinib in healthy subjects and subjects with rheumatoid arthritis from NCT01741493, NCT02066389, and NCT01960855 studies, published in the Clinical Pharmacokinetics
    • 06 Jun 2016 Results published in the Clinical Pharmacokinetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top